TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7935224
Drug: ISDN (0.1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (0.1%, solved in NaCl; dose 4.8 +/- 0.8 mg/h)
Study: 7935224
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl solution, 3 ml/h)
Study: 3428378
Drug: Four-site intradermal
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-site intradermal (i.d.) PCEC regimen
Study: 3428378
Drug: Eight-site intradermal
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight-site intradermal (i.d.) PCEC regimen
Study: 3428378
Drug: Three-site intramuscular
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-site intramuscular (i.m.) PCEC regimen
Study: 3428378
Drug: Subcutaneous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous regimen using suckling mouse brain (SMB) rabies vaccine
Study: 3428378
Drug: Human rabies
Normalized name: Human rabies virus immune globulin
DrugBank: Rabies immune globulin, human (DB11603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human rabies immune globulin therapy
Study: 26867075
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment for reducing hostility (12-week program)
Study: 24726294
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg IV over 20 hours
Study: 24726294
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of N-acetylcysteine (NAC) and infliximab (5 mg/kg IV as a single 2-hour administration)
Study: 20459775
Drug: mTOR-inhibitor-free immunosuppression
Normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR-inhibitor-free immunosuppression
Study: 19641760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group 3, 16 individuals, average age 10 years 4 months, no treatment for 10 months)
Study: 12748432
Drug: Postoperative subfascial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative subfascial infusion with 0.5% bupivacaine at 2 ml per hour for 48 hours
Study: 12748432
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics alone (nonpump group)
Study: 12748432
Drug: Postoperative subfascial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative subfascial infusion with 0.5% bupivacaine
Study: 10654982
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) 100 microg QD
Study: 9049515
Drug: Total cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cholesterol levels ≤ 160 mg/dl
Study: 9049515
Drug: Total cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cholesterol levels > 160 mg/dl (controls)
Study: 29656569
Drug: Iron‐folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron‐folic acid (IFA) capsules
Study: 29656569
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient (MMN) capsules
Study: 29656569
Drug: All supplements
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All supplements (SQ‐LNS, IFA, MMN)
Study: 23753114
Drug: GnRHa trigger
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRHa trigger (0.5 mg buserelin) followed by a single bolus of 1.500 IU hCG
Study: 23753114
Drug: GnRHa trigger
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRHa trigger (0.5 mg buserelin) followed by two boluses of 1.500 IU hCG
Study: 18707619
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 30,000 IU once weekly
Study: 18707619
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 20,000 IU once weekly
Study: 18707619
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (both doses)
Study: 16651750
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch 20 cm2 (TNP-20x1)
Study: 16651750
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch 20 cm2 (TNP-20x2)
Study: 16651750
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch 30 cm2 (TNP-30x1)
Study: 14672298
Drug: Meat supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat supplementation (60-85 g/d)
Study: 14672298
Drug: Milk supplementation
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplementation (200-250 mL/d)
Study: 30285891
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment for IBS (control group)
Study: 22350285
Drug: Sonophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonophoresis with SonoPrep® followed by EMLA® cream application
Study: 22350285
Drug: Sham sonophoresis
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham sonophoresis followed by EMLA® cream application
Study: 14664421
Drug: rHuEPO 600
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO 600 U/kg once weekly for three weeks plus iron supplementation
Study: 27565651
Drug: Investigational receptor‐specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational receptor‐specific partial agonist drug
Study: 18928632
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional hormonal therapy and immunosuppressive therapy)
Study: 16813184
Drug: Difference in
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difference in VAS after treatment between groups
Study: 14663473
Drug: Periprostatic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic injection anesthesia with 10 cm3 (5 cm3 each side) 1% lidocaine
Study: 11042231
Drug: Tiagabine 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 2.5, 5, 7.5 or 10 mg twice daily
Study: 29908336
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) with praise and financial incentives targeted at abstinence from opiates or attendance at treatment sessions
Study: 27737664
Drug: etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 60 mg (escalated to 90 mg)
Study: 27737664
Drug: etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg (continued)
Study: 27737664
Drug: naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 1000 mg (continued)
Study: 16791612
Drug: Topical hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydrocortisone (HC)
Study: 16791612
Drug: Topical hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydrocortisone (HC) with physiotherapy (PT)
Study: 12659547
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (pharmacotherapy and psychodynamic supportive psychotherapy)
Study: 9189727
Drug: Normal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal diet (NORM) for 3 days, 426 (137) g.day‐1 CHO [5.9 (1.4) g.kg‐1 body mass (BM)]
Study: 9189727
Drug: Additional carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional carbohydrate (SUPP) for 3 days, 661 (76) g.day‐1 CHO [9.3 (0.7) g.kg‐1 BM]
Study: 3104123
Drug: Transdermal Therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Therapeutic System releasing 10 mg of nitroglycerin over 24 hours (TTS 10)
Study: 3104123
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate 5 mg (ISDN)
Study: 26122982
Drug: Intervention package
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention package delivered by community midwives including psychoeducation, problem solving treatment, and parenting skills, with clinical support via mobile phone.
Study: 26122982
Drug: Care as
Normalized name: TopCare Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care as usual enhanced by further training of providers in recognition and standard treatment of depression.
Study: 20512335
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GJ) consumed 200 mL three times a day for three days prior to PK analysis.
Study: 7910880
Drug: Regular salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular salbutamol (2 puffs - 200 micrograms - four times daily)
Study: 20193095
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (10 microg daily)
Study: 20193095
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (10 microg daily) + Calcium (600 mg daily)
Study: 20193095
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient (including 10 microg Vitamin D) + Calcium (600 mg daily)
Study: 16511419
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (brief physician advice, self-help materials, nicotine replacement therapy)
Study: 8838965
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin (5 g loading dose, intravenous infusion twice, 4 h apart)
Study: 6342752
Drug: Primary radiation
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radiation therapy
Study: 9748717
Drug: Cefdinir 100
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 100 mg capsule (Cefzon)
Study: 9748717
Drug: Cefdinir 100
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 100 mg daily for 3 to 8 days
Study: 9748717
Drug: Cefdinir 200
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 200 mg (2 capsules) daily for 4 to 14 consecutive days
Study: 2971515
Drug: salbutamol, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol, 5 mg mixed with ipratropium bromide 500 micrograms
Study: 2971515
Drug: salbutamol, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol, 5 mg
Study: 12402423
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IL-2 and IFN-alpha
Study: 12402423
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of other cytokines (e.g., GM-CSF) or chemotherapy
Study: 29656500
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) for six months
Study: 21638162
Drug: Aquamid® filler,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquamid® filler, 8 ml per session, retreated every 8 weeks until full correction observed.
Study: 21638162
Drug: Aquamid® filler,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquamid® filler, 2 ml per session, retreated every 8 weeks until full correction observed.
Study: 18813866
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of Shoyu polysaccharides (SPS) daily for 2 weeks
Study: 18813866
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of Shoyu polysaccharides (SPS) daily for 4 weeks
Study: 10622347
Drug: Amisulpride 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 800 mg
Study: 1952008
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate ointment
Study: 1952008
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic mixture of local anaesthetics cream
Study: 31687933
Drug: Novel paclitaxel-coated
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Novel paclitaxel-coated drug-coated balloon (DCB)
Study: 29855986
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 (120 mg, twice a day)
Study: 24794703
Drug: Insulin analogues
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogues (detemir and aspart)
Study: 24794703
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (human neutral protamine Hagedorn and human regular)
Study: 22045363
Drug: Midodrine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (alpha agonist)
Study: 19551459
Drug: Lactose-[(13)C]ureide breath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-[(13)C]ureide breath test (LUBT) with 2 g of lactose-[(13)C]ureide
Study: 19551459
Drug: Glucose hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose hydrogen breath test (GHBT) with 50 g glucose
Study: 8602384
Drug: Nephrotoxic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrotoxic chemotherapy
Study: 8602384
Drug: Nonnephrotoxic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonnephrotoxic chemotherapy
Study: 8602384
Drug: Age effect
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age effect on pharmacokinetics
Study: 8602384
Drug: Gentamicin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin dosing
Study: 2669222
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose nebulised morphine (5 ml of morphine 1 mg/ml)
Study: 769773
Drug: Active electrosleep
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active electrosleep therapy
Study: 769773
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment (placebo)
Study: 26081587
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of telmisartan
Study: 21528641
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of mosapride citrate
Study: 21528641
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of mosapride citrate
Study: 8493803
Drug: Amino‐Mel hepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino‐Mel hepa + L‐valine (Group B)
Study: 27662264
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone
Study: 27662264
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral liquid formulation (5 to 15 mL)
Study: 27662264
Drug: Multiple dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing of oral liquid formulation
Study: 27662264
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral liquid formulation
Study: 23092665
Drug: Intravenous PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PPI followed by oral administration (group 2)
Study: 23092665
Drug: Oral PPIs
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PPIs alone (group 1)
Study: 20021657
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (AS) 2-5 mg/kg
Study: 20021657
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (AS)
Study: 20021657
Drug: High-fat and
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat and high-caloric meal prior to drug administration
Study: 18030711
Drug: Therapeutic angiogenesis
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic angiogenesis (cell transplantation, gene therapy, application of growth factors)
Study: 10924866
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 or 3000 mg
Study: 8810671
Drug: Reumalex, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reumalex, a licensed over-the-counter herbal medicine
Study: 1605451
Drug: Defibrotide (DF)
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide (DF) 400 mg i.v. given one hour prior to operation and twice daily for seven days postoperatively
Study: 1605451
Drug: Calcium-heparin (CH)
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-heparin (CH) 0.2 ml (5000 U.I.) subcutaneously given one hour prior to operation and twice daily for seven days postoperatively
Study: 1605451
Drug: Calcium-heparin (CH)
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-heparin (CH)
Study: 6420352
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release buccal nitroglycerin (23.4 mg daily)
Study: 3716918
Drug: Four hypnotic
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four hypnotic sessions with a booster
Study: 3716918
Drug: Two hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two hypnotic sessions
Study: 3716918
Drug: Two hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two hypnotic and two behavioral sessions with a booster
Study: 3716918
Drug: Four hypnotic
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four hypnotic sessions and a booster session (follow-up group)
Study: 25708324
Drug: Divaza preparation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divaza preparation, 12-week treatment course
Study: 16724578
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after a fat-rich breakfast (Treatment A)
Study: 16724578
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Neoral, Novartis AG, Basel, Switzerland, 200 mg) after a fat-rich breakfast (Treatment B)
Study: 16724578
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after fasting (Treatment C)
Study: 12774949
Drug: Anticonvulsants (AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsants (AC Group)
Study: 12774949
Drug: No anticonvulsants
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticonvulsants (No AC Group)
Study: 4005120
Drug: 10/170 Oros
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/170 Oros oxprenolol succinate (170 mg, initial release rate 10 mg/h)
Study: 4005120
Drug: 16/260 Oros
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16/260 Oros oxprenolol succinate (260 mg, initial release rate 16 mg/h)
Study: 4005120
Drug: Slow Trasicor
Normalized name: Slow Trasicor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Trasicor (160 mg once daily)
Study: 4005120
Drug: Trasicor (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trasicor (80 mg twice daily)
Study: 30804818
Drug: Mobile app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app-based intervention (treatment as usual plus five modules: psychoeducation, recognition of symptoms and prevention of relapses, problem solving, mindfulness, and contact wall)
Study: 27746007
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and metronidazole for 5 days postoperatively
Study: 27746007
Drug: Placebo (identical-looking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-looking drugs)
Study: 12860216
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 to 80 mg
Study: 12860216
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 to 40 mg
Study: 12860216
Drug: atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10 to 80 mg
Study: 10651663
Drug: LAM-2 W
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 2 weeks)
Study: 10651663
Drug: LAM-1 W
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM-1 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 1 week and placebo)